Photo of Christopher W. Ryan, MD

Christopher W. Ryan MD

Dr. Ryan specializes in the treatment of sarcomas (rare bone and soft tissue tumors) and genitourinary cancers (kidney, bladder, prostate and testicle cancers). He strives to offer the latest treatments to his patients through clinical trials. He is inspired by his many patients who received breakthrough treatments in clinical trials before those treatments were widely available.

Dr. Ryan enjoys the Oregon outdoors, fly fishing for steelhead and cycling when he is given the chance. Most of all, he enjoys spending time with his wife and two small children.

Read more
  • Residency:

    • Internal medicine, University of Chicago, 1997
  • Fellowship:

    • Hematology/oncology, University of Chicago, 2000
  • Certifications:

    • American Board of Internal Medicine (medical oncology), 2000

Memberships and associations

  • American Society of Clinical Oncology


  • "Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results : Analysis of Phase 3 SWOG Intergroup Trial S0033." JAMA oncology In: , Vol. 3, No. 7, 01.07.2017, p. 944-952.
  • "Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma." Journal of Oncology Pharmacy Practice In: , Vol. 23, No. 1, 01.01.2017, p. 43-55.
  • "Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021) : An international, multicentre, open-label, randomised phase 3 trial." The Lancet Oncology  In: , 2017.
  • "PICASSO III : A phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma." Journal of Clinical Oncology  In: , Vol. 34, No. 32, 10.11.2016, p. 3898-3905.
  • "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN) : A multicentre, open-label, randomised phase 2 trial." The Lancet Oncology In: , Vol. 17, No. 3, 01.03.2016, p. 378-388.
  • "Metastatic renal cell carcinoma without evidence of a renal primary." International Urology and Nephrology In: , Vol. 48, No. 1, 01.01.2016, p. 73-77.
  • "Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity." Urologic Oncology: Seminars and Original Investigations  In: , Vol. 34, No. 1, 01.01.2016.
  • "Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer." Oncology Nursing Forum In: , Vol. 42, No. 4, 01.07.2015, p. 348-356.
  • "Preoperative Therapy for Extremity Soft Tissue Sarcomas." Current Treatment Options in Oncology In: , Vol. 16, No. 6, 16.06.2015.
  • "A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer." Clinical Genitourinary Cancer  In: , Vol. 13, No. 2, 01.04.2015, p. 113-123.
  • "A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer." Investigational New Drugs  In: , Vol. 33, No. 2, 01.04.2015, p. 480-489.
  • "Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy : Evidence from a randomized controlled trial." Archives of Physical Medicine and Rehabilitation In: , Vol. 96, No. 1, 01.01.2015, p. 7-14.
  • "Effect of dutasteride in men receiving intermittent androgen ablation therapy : The AVIAS trial." Journal of the Canadian Urological Association  In: , Vol. 8, No. 11-12, 01.11.2014, p. e789-e794.
  • "Skeletal response to resistance and impact training in prostate cancer survivors." Medicine and Science in Sports and Exercise In: , Vol. 46, No. 8, 2014, p. 1482-1488.
  • "Phase i trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates." Clinical Cancer Research In: , Vol. 19, No. 24, 15.12.2013, p. 6902-6911.
  • "A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma." Investigational New Drugs In: , Vol. 31, No. 1, 02.2013, p. 145-151.
  • "Overcoming autopsy barriers in pediatric cancer research." Pediatric Blood and Cancer  In: , Vol. 60, No. 2, 02.2013, p. 204-209.
  • "A molecular case report : Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma." Cancer Biology and Therapy In: , Vol. 14, No. 2, 02.2013, p. 95-99.
  • "MDM2 amplification and PI3KCA mutation in a case of sclerosing rhabdomyosarcoma." Sarcoma  In: , Vol. 2013, 520858, 2013.
  • "The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma." American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting  In: , 2013.
  • "Promise and pitfalls of quantitative imaging in oncology clinical trials." Magnetic Resonance Imaging In: , Vol. 30, No. 9, 11.2012, p. 1301-1312.
  • "Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer." Journal of Clinical Oncology In: , Vol. 30, No. 5, 10.02.2012, p. 507-512.
  • "Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas." Cancer  In: , Vol. 118, No. 3, 01.02.2012, p. 770-776.
  • "Adjuvant systemic therapy for renal cell carcinoma."  Kidney Cancer: Principles and Practice. Springer Berlin Heidelberg, 2012. p. 172-186.
  • "A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma." Investigational New Drugs  In: , Vol. 29, No. 2, 04.2011, p. 374-379.
  • "Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program." Oncology In: , Vol. 78, No. 5-6, 09.2010, p. 340-347.
  • "A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy." Anti-Cancer Drugs In: , Vol. 21, No. 4, 04.2010, p. 433-438.
  • "Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America." Cancer In: , Vol. 116, No. 5, 01.03.2010, p. 1272-1280.
  • "Editorial Comment." Journal of Urology In: , Vol. 182, No. 6, 12.2009, p. 2675.
  • "Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer." Clinical Cancer Research In: , Vol. 15, No. 22, 15.11.2009, p. 7099-7105.

Additional information

Edit profile